Aktienanalyse zu Marker Therapeutics Inc (MRKR)MRKRMarker Therapeutics Inc

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Marker Therapeutics Inc is currently not a good buy due to its declining revenue and negative earnings, despite a recent uptick in stock price. The current price is $0.92, and the stock has a low RSI of 37.105, indicating it is oversold. The company reported a significant year-to-date change of -40.49% and a 5-day change of -6.48%, reflecting ongoing struggles. The main risk is its forward P/E ratio of 0, suggesting no expected profitability in the near term, which could deter long-term investors.